Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

INTRODUCTION: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Haitao, Liu, Jiayu, Deng, Wentong, Xing, Jieyu, Li, Qing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985803/
https://www.ncbi.nlm.nih.gov/pubmed/29881272
http://dx.doi.org/10.2147/IJN.S164542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985803/
https://www.ncbi.nlm.nih.gov/pubmed/29881272
http://dx.doi.org/10.2147/IJN.S164542

Ejemplares similares